AGPU AGPU Drug Discovery Services — Deferred Revenue

Other product segments

Similar metrics at other companies

SDGRDrug discovery — Deferred Revenue

$42.36M-5.6%

SDGRDrug discovery — Deferred revenue, revenue recognized

$22.4M+189%

SDGRDrug discovery — Deferred revenue, long-term

$52.82M-42.5%

FDMTDeferred Revenue — Deferred Revenue

$2.49M—

SDGRDrug Discovery Services — Drug discovery services revenue from contracts with customers

$11.7M+105%

DUOTServices And Consulting — Deferred Revenue

$166.45K—

Questions, answered.

What is AGPU's drug discovery services — deferred revenue?

AGPU (AGPU) reported drug discovery services — deferred revenue of $100K in Q1 2026.

What does drug discovery services — deferred revenue mean?

This metric represents the obligation of the drug discovery services segment to transfer goods or services to a customer for which the company has already received consideration or has an unconditional right to consideration. It typically arises from deferred revenue where payments are received in advance of fulfilling research milestones or service delivery. This balance is a key indicator of future revenue recognition and the segment's ability to fulfill its contractual commitments.